PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.51%
Revenue growth at 75-90% of META's 12.29%. Bill Ackman would push for innovation or market expansion to catch up.
11.86%
Gross profit growth similar to META's 12.33%. Walter Schloss would assume both firms track common industry trends.
14.22%
EBIT growth 1.25-1.5x META's 10.27%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
14.22%
Operating income growth at 75-90% of META's 16.44%. Bill Ackman would demand a plan to enhance operating leverage.
1.70%
Net income growth under 50% of META's 10.17%. Michael Burry would suspect the firm is falling well behind a key competitor.
1.17%
EPS growth under 50% of META's 10.47%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
1.20%
Diluted EPS growth under 50% of META's 11.04%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.56%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.36%
Slight or no buyback while META is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
19.48%
OCF growth above 1.5x META's 6.39%. David Dodd would confirm a clear edge in underlying cash generation.
1593.20%
Positive FCF growth while META is negative. John Neff would see a strong competitive edge in net cash generation.
1476.77%
10Y revenue/share CAGR 1.25-1.5x META's 1223.16%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
1476.77%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
480.51%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
547.00%
3Y OCF/share CAGR above 1.5x META's 125.05%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
1777.31%
Net income/share CAGR at 50-75% of META's 2770.56%. Martin Whitman might question if the firm’s product or cost base lags behind.
1777.31%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
3018.11%
3Y net income/share CAGR above 1.5x META's 194.47%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.49%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
No Data
No Data available this quarter, please select a different quarter.
9.01%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
7.18%
1.25-1.5x META's 5.80%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
10.65%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
7.57%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.